Why This Matters: Canada’s current approach to valuing innovative medicines is overly focused on low prices while missing the full value they bring to patients, caregivers, the health system, and the economy. Canada needs to move beyond a lowest-price mindset. When innovation is undervalued, patients pay the price through delayed or limited access to life-saving medicines.